Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

202245 citationsJournal Articlehybrid Open Access

Authors

Hironori Ochi · Matsuyama Red Cross Hospital

Masayuki Kurosaki · Musashino Red Cross Hospital

Kouji Joko · Matsuyama Red Cross Hospital

Toshie Mashiba · Matsuyama Red Cross Hospital

Nobuharu Tamaki · Musashino Red Cross Hospital

Kaoru Tsuchiya · Musashino Red Cross Hospital

Hiroyuki Marusawa

Abstract

Pretreatment NLR is a simple tool for routine measurement in clinical practice. It can predict PFS in patients with unresectable HCC treated with atezolizumab plus bevacizumab, especially mALBI grade 1 or 2a.

Topics & Keywords

Inflammatory Biomarkers in Disease Prognosis Hepatocellular Carcinoma Treatment and Prognosis Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology Research

Volume 53, Issue 1, pp. 61-71

DOI: 10.1111/hepr.13836

Field-Weighted Citation Impact: 4.60